TFDA takes actions to help mitigate supply disruptions or shortages of drug

摘要

During the COVID-19 pandemic, governments around the globe impose quarantines, lockdowns and transportation reductions to slow the spread of the disease. These control measures disrupt normal business operations which in- cludes the pharmaceutical industries. Potential supply chain disruption are foreseen when the two world’s largest active pharmaceutical ingredient (API) producers and sup- pliers, China and India, shut down the manufactures and restrict the pharmaceuticals exportation. Taiwan Food and Drug Administration (TFDA) has thus taken several preven- tive and proactive actions to fight the disease and to pro- tect public health during the supply disruption scares.